Our Pipeline

BROAD INFLAMMATION & IMMUNOLOGY PIPELINE OF CANDIDATES WITH NOVEL MECHANISMS

We own worldwide development and commercialization rights to each of our product candidates.

PathwayProgramIndicationPreclinicalIND-EnablingPhase IPhase IIPhase III
LANCL2Omilancor (BT-11)Ulcerative Colitis
Crohn's Disease
Eosinophilic Esophagitis
Psoriasis
Atopic dermatitis
LABP-104Lupus
Rheumatoid Arthritis
LABP-111NASH
Type 1 Diabetes
NLRX1NX-13Ulcerative Colitis
Crohn's Disease
LABP-66Multiple Sclerosis
Alzheimer's Disease
LABP-73Asthma
COPD
PLXDC2LABP-69Diabetic Nephropathy
Rheumatoid Arthritis

Omilancor Exerts Anti-Inflammatory Effects within the Gastrointestinal Tract

Omilancor (BT-11), our lead product candidate, is a first-in-class, gut-restricted oral therapeutic candidate that targets LANCL2, a membrane receptor that has been shown to modulate immunological mechanisms that are associated with various autoimmune diseases such as ulcerative colitis (UC) and Crohn’s disease (CD).

In January 2021, Landos announced initial results from its Phase 2 proof-of-concept trial of omilancor in patients with mild-to-moderate UC. The results demonstrated that omilancor was gut-restricted and well tolerated, with a similar adverse event profile across placebo and omilancor groups. In addition, omilancor induced placebo-adjusted clinical remission rates of up to 11.5% at week 12, with normalization of biomarkers such as fecal calprotectin observed after two weeks of oral dosing. Based on clinical data to date, omilancor may address the main limitations of current therapies by providing a convenient once a day dosing that offers low systemic exposure, improved tolerability and no ties to toxicities. Encouraged by the results from the Phase 2 trial, Landos expects to initiate a Phase 3 trial of omilancor in 2021 for patients with mild-to-moderate UC.

Additionally, Landos initiated a Phase 2 trial in May 2021 to evaluate proof of concept efficacy and safety of omilancor in patients affected by moderate-to-severe CD. Landos also expects to initiate a Phase 1b trial of omilancor in a third indication, Eosinophilic Esophagitis (EoE), in the first half of 2022.

BT-11 Diagram

Reprogramming Immune Responses in Autoimmune Diseases

NX-13 Modulates Epithelial Integrity and Mucosal Immune Responses in the Gastrointestinal Tract

NX-13 is a first-in-class novel, gut-restricted oral therapeutic candidate that targets NLRX1 (NOD-like receptor X1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines for UC and CD.

In March 2021, Landos reported positive results from a Phase 1a trial of NX-13 in healthy volunteers, for which all primary and secondary endpoints in safety and tolerability were achieved. In April 2021, Landos initiated a Phase 1b trial to evaluate the safety and pharmacokinetics of multiple dose levels of NX-13 in patients with UC.

NX-13 Diagram

NX-13